Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.52 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 3/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | MPL | P40238 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31262691 | 0.82 | MAP4K1 (0.55) | ASIC3NOS3MAP4K1NOS1 | |
| SCHEMBL30166486 | 0.79 | MPL (0.55) | ASIC3NOS3NOS2BACE1ALOX5AP | |
| SCHEMBL3935260 | 0.79 | MPL (0.55) | ASIC3NOS3NOS2BACE1ALOX5AP | |
| SCHEMBL29601960 | 0.78 | ASIC3 (0.68) | ASIC3NOS3NOS2BACE1IDH1 | |
| SCHEMBL1073895 | 0.78 | ASIC3 (0.68) | ASIC3NOS3NOS2BACE1IDH1 | |
| SCHEMBL3925102 | 0.78 | ASIC3 (0.47) | ASIC3NOS3NOS2BACE1REV1 | |
| SCHEMBL30883058 | 0.78 | ASIC3 (0.47) | ASIC3NOS3NOS2BACE1REV1 | |
| SCHEMBL29899251 | 0.76 | NOS3 (0.54) | ASIC3NOS3NOS2IDH1PDPK1 | |
| SCHEMBL18807016 | 0.74 | CCR1 (0.62) | NOS3NOS2IDH1F2RL3 | |
| SCHEMBL28513246 | 0.74 | HSP90AA1 (0.53) | FEN1SMN1; SMN2KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| EP-2661433-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | Novartis AG (CH) | 2013-11-13 | — | — | EP | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2012093101-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2012-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295884-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | ASIC3 2821/4885NOS3 3217/4885NOS2 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.